Indications for the use of angiotensin-converting enzyme (ACE) inhibitors are increasing. These include hypertension, heart failure, myocardial infarction, diabetic nephropathy, and proteinuric renal disease. ACE inhibitors have several neurohumoural actions beyond blockade of the renin-angiotensin system; in particular, the potentiation of bradykinin is considered responsible for some of their sideeffects.'
Renal problems with ACE inhibitors have been noted from their inception. In one recent report, 16% of cases of acute renal failure were attributed to the use of ACE inhibitors.2 Most commonly, where there is critical renovascular disease, glomerular filtration is severely reduced in the presence of ACE inhibitors, as efferent renal arteriolar tone, upon which infiltration then depends, is exquisitely dependent on angiotensin II. Though most investigators invoke this angiotensin mechanism to explain deterioration in renal function after the use of ACE inhibitors, there has been speculation that bradykinin may also be relevant.'
In part because of these side-effects, and from pharmacological considerations, research has focused on producing selective antagonists of angiotensin II, at the level of the cellular angiotensin AT1 receptor.' The S?if" Jl.:.;rfHl ''''':ii. ." Figure 1 Chest X-ray on the morning of the third post-operative day
